The Reports and Insights, a leading market research company, has recently releases report titled “Faba Bean Protein Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global Faba Bean Protein Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights:
How big is the Faba Bean Protein Market?
The global faba bean protein market size was US$ 5.8 Billion in 2022. Global market revenue is expected to register a revenue CAGR of 5.1% during the forecast period and reach a market size of US$ 9.1Bn in 2031.
What are Faba Bean Protein?
Faba bean protein, sourced from the faba bean, also known as broad or fava bean, is a high-quality plant-based protein that provides all nine essential amino acids necessary for human health. It is also rich in fiber, vitamins, and minerals, making it a nutritious option for vegetarians, vegans, and those seeking to incorporate more plant-based proteins into their diets. Furthermore, faba bean protein is environmentally sustainable, as faba beans require less water and generate fewer greenhouse gas emissions compared to animal-derived proteins.
Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2048
What are the growth prospects and trends in the Faba Bean Protein industry?
The faba dean protein market growth is driven by various factors. The market for faba bean protein is expanding rapidly, driven by the increasing consumer interest in plant-based proteins. This surge in demand is fueled by factors such as growing health awareness, ethical and environmental considerations, and a rising number of individuals adopting vegan and vegetarian lifestyles. Moreover, advancements in food processing techniques have enhanced the taste and quality of faba bean protein products, contributing to their growing popularity in the market. Hence, all these factors contribute to faba dean protein market growth.
What is included in market segmentation?
The report has segmented the market into the following categories:
By Product Type:
- Concentrates
- Isolates
Form:
- Powder
- Liquid
Application:
- Food & Beverages
- Nutritional Supplements
- Animal Feed
End-User:
- Retail
- Food Service
- Industrial
Distribution Channel:
- Direct Sales
- Online Retail
- Specialty Stores
- Hypermarkets/Supermarkets
- Others
Segmentation By Region:
North America:
- United States
- Canada
Europe:
- Germany
- The U.K.
- France
- Spain
- Italy
- Russia
- Poland
- BENELUX
- NORDIC
- Rest of Europe
Asia Pacific:
- China
- Japan
- India
- South Korea
- ASEAN
- Australia & New Zealand
- Rest of Asia Pacific
Latin America:
- Brazil
- Mexico
- Argentina
Middle East & Africa:
- Saudi Arabia
- South Africa
- United Arab Emirates
- Israel
Who are the key players operating in the industry?
The report covers the major market players including:
- Roquette Frères
- Axiom Foods
- Burcon NutraScience Corporation
- AGT Food and Ingredients
- Emsland Group
- Cargill, Incorporated
- Ingredion Incorporated
- Cosucra Group Warcoing SA
- Parabel USA Inc.
- Nutriati, Inc.
- Farbest Brands
- Verdient Foods Inc.
- Plantible Foods Inc.
- Shandong Jianyuan Group Co., Ltd.
- Legumex Walker Inc.
View Full Report: https://www.reportsandinsights.com/report/Faba Bean Protein-market
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
Reports and Insights Business Research Pvt. Ltd.
1820 Avenue M, Brooklyn, NY, 11230, United States
Contact No: +1-(347)-748-1518
Email: [email protected]
Website: https://www.reportsandinsights.com/
Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/
Follow us on twitter: https://twitter.com/ReportsandInsi1
Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight (Albany, US) DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.Key Highlights from report are:As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017.
These cases are expected to grow with a significant CAGR in the study period 2017–2030.There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.The market size of NSCLC in the 7MM is expected to increase during study period.
According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.Request for free sample pages to know more on Non-Small Cell Lung Cancer Market Forecast NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers.
The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.Click here to know more on Non-Small Cell Lung Cancer pipelineNSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many others Key Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.
Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.
